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Prostaglandin metabolite induces inhibition of
TRPA1 and channel-dependent nociception
Yingqi Weng1,2,3, Patricia A Batista-Schepman1,2,4, Marie E Barabas5, Eli Q Harris1,2, Thomas B Dinsmore1,2,
Elena A Kossyreva5, Audra M Foshage1,2, Michelle H Wang1,2, Matthew J Schwab1,2, Victoria M Wang1,2,
Cheryl L Stucky5 and Gina M Story1,2*

Abstract
Background: The Transient Receptor Potential (TRP) ion channel TRPA1 is a key player in pain pathways. Irritant
chemicals activate ion channel TRPA1 via covalent modification of N-terminal cysteines. We and others have shown
that 15-Deoxy-Δ12, 14-prostaglandin J2 (15d-PGJ2) similarly activates TRPA1 and causes channel-dependent
nociception. Paradoxically, 15d-PGJ2 can also be anti-nociceptive in several pain models. Here we hypothesized that
activation and subsequent desensitization of TRPA1 in dorsal root ganglion (DRG) neurons underlies the
anti-nociceptive property of 15d-PGJ2. To investigate this, we utilized a battery of behavioral assays and intracellular
Ca2+ imaging in DRG neurons to test if pre-treatment with 15d-PGJ2 inhibited TRPA1 to subsequent stimulation.
Results: Intraplantar pre-injection of 15d-PGJ2, in contrast to mustard oil (AITC), attenuated acute nocifensive
responses to subsequent injections of 15d-PGJ2 and AITC, but not capsaicin (CAP). Intraplantar 15d-PGJ2—
administered after the induction of inflammation—reduced mechanical hypersensitivity in the Complete Freund’s
Adjuvant (CFA) model for up to 2 h post-injection. The 15d-PGJ2-mediated reduction in mechanical hypersensitivity
is dependent on TRPA1, as this effect was absent in TRPA1 knockout mice. Ca2+ imaging studies of DRG neurons
demonstrated that 15d-PGJ2 pre-exposure reduced the magnitude and number of neuronal responses to AITC, but
not CAP. AITC responses were not reduced when neurons were pre-exposed to 15d-PGJ2 combined with
HC-030031 (TRPA1 antagonist), demonstrating that inhibitory effects of 15d-PGJ2 depend on TRPA1 activation.
Single daily doses of 15d-PGJ2, administered during the course of 4 days in the CFA model, effectively reversed
mechanical hypersensitivity without apparent tolerance or toxicity.
Conclusions: Taken together, our data support the hypothesis that 15d-PGJ2 induces activation followed by
persistent inhibition of TRPA1 channels in DRG sensory neurons in vitro and in vivo. Moreover, we demonstrate
novel evidence that 15d-PGJ2 is analgesic in mouse models of pain via a TRPA1-dependent mechanism.
Collectively, our studies support that TRPA1 agonists may be useful as pain therapeutics.
Keywords: TRPA1, 15d-PGJ2, Mustard oil, Negative modulation, Mechanical hypersensitivity

Background
Transient receptor potential cation channel subfamily A
member 1 (TRPA1) was first identified as a channel activated by noxious cold (~10-17°C) and was thus included
in the temperature-gated subfamily termed “thermoTRPs”
[1,2]. Whether TRPA1 is directly activated by cold and if it
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plays a role in thermosensation in vivo remain equivocal
and debated issues in the somatosensory field [3-5]. However, its activation by a variety of noxious chemicals is
widely accepted. The catalogue of TRPA1 chemical agonists is burgeoning and includes a variety of exogenous, as
well as endogenous, compounds. We and others identified
15d-PGJ2, a multi-functional prostaglandin molecule, as
an endogenous TRPA1 activator. Similar to other TRPA1
agonists, intraplantar (ipl.) administration of high concentrations (relative to physiological levels) of 15d-PGJ2
causes TRPA1-dependent nocifensive behavior [6-9].
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15d-PGJ2, one of three J-series prostaglandin D2 metabolites, is the most recently discovered prostaglandin with a
proposed role as an endogenous anti-inflammatory agent
[10]. 15d-PGJ2 activates molecules in anti-inflammatory
pathways through covalent modification of cysteine residues. This occurs because of its reactive cyclopentenone
ring, which readily reacts with nucleophilic cysteine groups
through the Michael addition reaction [11]. This has been
shown using non-reactive analogues of 15d-PGJ2 and by
mutagenizing cysteine residues of target proteins such as
IkappaB kinase and PPARγ [12-16]. Similarly, cysteine
residues of TRPA1 can be modified by certain electrophilic
agonists, which leads to activation of the channel by chemicals of this class [11,17,18].
Recent findings support that 15d-PGJ2 also exhibits
anti-nociceptive properties [9,19,20]. Here we demonstrate a novel TRPA1-dependent anti-nociceptive modality of 15d-PGJ2 in acute nociception and mechanical
hypersensitivity. Although the pro- and anti-nociceptive
effects of 15d-PGJ2 may seem mutually exclusive, we
propose a mechanism based on our data that reconciles
these seemingly opposing effects. We hypothesize that
15d-PGJ2 is anti-nociceptive owing in part to its ability
to activate and desensitize TRPA1 in peripheral nociceptive fibers.
Our findings support this hypothesis. Peripheral injection of a pro-nociceptive and behaviorally desensitizing
dose of 15d-PGJ2 produces an attenuation of acute nocifensive behavior induced by AITC, whereas AITC itself
does not produce such effects. Correspondingly, we find
that 15d-PGJ2 produces a marked inhibition of subsequent
responses to AITC in DRG neurons. When administered
after the induction of inflammation, 15d-PGJ2 reduces
mechanical hypersensitivity in WT but not TRPA1 knockout (TRPA1−/−) mice, arguing that these analgesic effects
are mediated via the channel. Taken together our data
suggest that 15d-PGJ2 induces a reduction of chemical
and mechanical nociception via initial activation and subsequent inhibition of TRPA1. Results also indicate that
this property may be unique to 15d-PGJ2 as an endogenous TRPA1 activator, as AITC did not have the same
effects in behavioral assays or in DRG neurons.

Results
Effects of 15d-PGJ2 on mechanosensitivity

We hypothesized that 15d-PGJ2 is anti-nociceptive
owing in part to its ability to activate, and subsequently
desensitize, TRPA1. We set out to test whether 15dPGJ2 is anti-nociceptive in pain models in which a role
of TRPA1 is implicated. After the induction of mechanical hypersensitivity by CFA, TRPA1-selective antagonists AP-18 and HC-030031 ameliorate post-CFA
mechanical thresholds in WT but not TRPA1−/− mice
[21-23]. Therefore, we utilized the CFA model to
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investigate whether 15d-PGJ2 could reverse inflammatory mechanical hypersensitivity.
In separate groups of mice, we measured mechanical
thresholds using the up and down method at baseline
and 24 h post-CFA injection (day 1, Figure 1A). One day
after CFA injection, we injected 1.5 or 15 mM 15d-PGJ2
(10 μL) into the plantar hindpaw 1 h prior to von Frey
measurements. As shown in Figure 1A, 15 mM 15dPGJ2 induced a marked reversal of mechanical hypersensitivity relative to vehicle (and 1.5 mM 15d-PGJ2). The
effect was maximal at 2 h post injection. In contrast,
15d-PGJ2 had no effect on heat hypersensitivity as measured with the Hargreaves assay, suggesting that the effect of 15d-PGJ2 is modality specific (Figure 1B).
Administering 15d-PGJ2 prior to the induction of inflammation by CFA had no effect on mechanical thresholds in CFA- or vehicle-injected mice (data not shown,
see also below).
Previous studies characterizing the analgesic effects
of 15d-PGJ2 do not report whether the compound
alters baseline mechanical sensitivities in naïve/uninjured rodents [9,19,20]. Therefore, we also investigated whether ipl. injection of 15 mM 15d-PGJ2,
administered 1 h prior to von Frey testing, caused
any change in mechanical thresholds relative to
vehicle-injected controls. As shown in Figure 1C,
mechanical sensitivities of 15d-PGJ2 and vehicleinjected mice did not significantly differ. This indicates that 15d-PGJ2 does not generate mechanical
hypo- or hypersensitivity. In contrast, pre-injection of
an equivalent concentration of AITC (15 mM) caused
a significant reduction in paw withdrawal threshold,
indicative of hyperalgesia (Figure 1C). These results
are similar to studies showing that AITC and cinnamaldehyde induce significant mechanical hyperalgesia
in rats [24,25]. Furthermore, our data also suggest
disparate in vivo effects of the two TRPA1 agonists
15d-PGJ2 and AITC.
15d-PGJ2 and AITC evoke equivalent nocifensive behavior

We reasoned that the different pharmacological effects
of 15d-PGJ2 and AITC could be due to their relative potencies in vivo. Though the two TRPA1-specific compounds have similar in vitro EC50 values, in vivo
potencies have not been directly compared [7]. Therefore, we performed dose–response analysis using two
concentrations of 1.5 and 15 mM 15d-PGJ2 or AITC
(10 μL, ipl.). To determine both the magnitude and duration of nocifensive behaviors at each dose of the two
compounds, we recorded at 10-min intervals for 1 h.
Figure 2 illustrates the total nocifensive response at 10-min
increments (A-B) and the total duration (C) of nocifensive
responses during the course of 40 min at each concentration of 15d-PGJ2 and AITC. 15d-PGJ2- and AITC-induced
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Figure 1 Effect of 15d-PGJ2 on mechanical- and heat-sensitivity.
(A) 15 mM 15d-PGJ2 (ipl.) attenuates CFA-induced mechanical
hypersensitivity. Von Frey measurements were recorded before CFA
injection (Naïve), 24 h post-CFA injection and at noted time points.
15d-PGJ2 was administered 1 h prior to von Frey measurements. (B)
15d-PGJ2 shows no analgesic effect (no change latency to licking or
flicking) against inflammatory heat hypersensitivity in Hargreaves
test. (C) 15d-PGJ2 itself does not cause mechanical hypersensitivity
(1 h after ipl. injection), while AITC does (*p < 0.05, **p < 0.01, ***
p < 0.001; n = 8 per group; values expressed as mean ± SEM). Data
were analyzed using RMANOVA with Bonferonni post-hoc
comparisons (A) or two-tailed Student’s t-test (B and C).

nocifensive behaviors consisted of licking, deliberate lifting
and shaking of the injected hindpaw. Nocifensive behaviors
subsided approximately 40 min after injection of 15 mM
or 1.5 mM of 15d-PGJ2 or AITC (Figure 2 A-B, data not
shown). The efficacy of 15 and 1.5 mM 15d-PGJ2 and
AITC in producing total nocifensive responses were
equivalent (Figure 1C). For both 15d-PGJ2 and AITC,
0.15 mM doses did not induce significant nocifensive behaviors compared to vehicle (data not shown). The 0.15 mM
dose of 15d-PGJ2 (475 ng/paw) is similar to another study
(300 ng/paw), which also did not report nocifensive behavior [19].

Behavioral desensitization of 15d-PGJ2 versus AITC

Previously it was reported that the second response to
ipl. injection of 0.1% (10 mM) AITC, administered
15 min after the first injection, is significantly reduced in
rats [26]. However, another more recent study in mice
demonstrated that nocifensive responses to the second
injection of 10 mM AITC, administered 10 min after the
first, sensitize significantly [27]. The discrepancy between these two studies could arise from differences in
dosing protocols or due to species differences. We determined whether 15d-PGJ2 inhibits TRPA1-dependent
nociception in vivo via a simple cross-desensitization
mechanism and whether this property of 15d-PGJ2 is
distinct from AITC. Our experiment was designed to
more carefully examine behavioral desensitization of
15d-PGJ2 vs. AITC responses in vivo. We used a 1 h
inter-stimulus interval to correspond with our dosing
paradigm(s) in the above CFA model. In addition, our
design aimed to ensure that nocifensive responses to the
first dose of both compounds had completely subsided
prior to administering the second dose.
We first examined desensitization of behavioral
responses to repeated 15d-PGJ2 stimuli and tested
whether 15d-PGJ2 could inhibit subsequent responses to
AITC. Unlike the AITC multi-dose results (Figure 3B),
two injections (10 μL each, ipl.) of 15 mM 15d-PGJ2
produced significant reductions of the second nocifensive response to 15 mM 15d-PGJ2 and to AITC at
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15 mM and at concentrations as high as 50 mM
(Figure 3A and data not shown). The anti-nociceptive effect of 15 mM 15d-PGJ2 was locally mediated as ipl. injection in the contralateral hindpaw 1 h prior to ipl.
injection of AITC did not significantly reduce AITCinduced nocifensive behavior (total nocifensive response
83 ± 15 sec vs. 97 ± 7 sec, p > 0.05).
Next, we tested whether 15 mM AITC could inhibit nocifensive responses to a subsequent injection of 15 mM 15dPGJ2 via cross-desensitization. Pre-injection of 15 mM
AITC did not induce cross-desensitization of behavioral
responses to 15 mM 15d-PGJ2 (10 μL each, ipl.)
(Figure 3B). We also did not observe homologous behavioral sensitization or desensitization as the nocifensive response to a second injection of 15 mM AITC was
equivalent to that evoked by 15 mM AITC administered
1 h prior (and relative to vehicle pre-injection) (Figure 3B).
The highest tested dose of AITC (50 mM) also did not inhibit nocifensive responses to a subsequent injection of
15 mM 15d-PGJ2 (1 h inter-stimulus; data not shown).
These data demonstrate that behavioral desensitization to a
second TRPA1-dependent noxious stimulus is not due to
the noxious nature of the first stimulus. These data suggest
that 15d-PGJ2 induces behavioral desensitization to itself
and to AITC. In contrast, ATIC does not induce
desensitization to itself or 15d-PGJ2.
15d-PGJ2 vs. AITC inhibition in DRG

Figure 2 Dose–response of nocifensive behavior evoked by
15d-PGJ2 or AITC. Mice were administered (10 μL ipl.) 15d-PGJ2 (A)
or AITC (B). Licking and deliberate lifting of the injected hindpaw
was recorded at 10-min intervals for 40 min. (C) Total nocifensive
response for 15d-PGJ2 vs. AITC are equivalent at 1.5 and 15 mM.
(*p < 0.05, **p < 0.01 for 15 mM 15d-PGJ2 vs. vehicle at 10 and
20 min time points, respectively; ***p < 0.01 for 15 mM ATIC vs.
vehicle; n = 6-8 per group; values expressed as mean ± SEM). Data
were analyzed using RMANOVA with Bonferonni post-hoc
comparisons.

In our previous publication characterizing 15d-PGJ2 activation of TRPA1-expressing DRG neurons, we showed
that 15d-PGJ2 activated ~19% of total DRG neurons and
that 98% of these also responded to AITC. We also
demonstrated that 15d-PGJ2 responses by DRG neurons
were absent in cultures derived from TRPA1−/− mice [6].
Collectively, these data indicate that 15d-PGJ2 is a selective agonist at TRPA1. We further hypothesized that a potential mechanism for the reported anti-nociceptive
properties of 15d-PGJ2 [9,19,20] is excitation and subsequent inhibition/desensitization of DRG neurons expressing TRPA1. Therefore, in order to evaluate whether
15d-PGJ2 could desensitize TRPA1-expressing nociceptors
to other agonists, we utilized Fura-2 Ca2+ imaging in DRG
neurons, to compare responses to 15d-PGJ2 and AITC in
vehicle-, 15d-PGJ2- and AITC- pre-stimulated cultures.
We conducted cross- and homologous-inhibition
experiments utilizing two bath applied pulses of 50–
100 μM 15d-PGJ2 or AITC. As shown in Figure 4,
100 μM 15d-PGJ2 strongly inhibits subsequent responses
to a pulse of 100 μM AITC applied up to 8 min later
(Figure 4A) and to itself (Figure 4B). Similarly, 100 μM
ATIC strongly desensitizes subsequent responses to
100 μM 15d-PGJ2 (Figure C) and to itself (Figure 4D).
Cross-desensitization was maintained when we applied
two pulses of 50 μM of each compound (data not
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Figure 3 Homologous and heterologous desensitization of 15d-PGJ2 vs. AITC. Multi-dose experiments 15d-PGJ2 (A) or AITC (B) cause
homologous or heterologous desensitization in vivo, we performed multi-dose experiments. The inter-stimulus interval was 1 h. Pre-injection (10
μL ipl.) of vehicle was used as control. Behavior was recorded at 10-min intervals for 30–40 min. (A) Nocifensive response to 15 mM 15d-PGJ2 or
50 mM AITC after 15 mM 15d-PGJ2 pre-injection was significantly reduced relative to vehicle pre-injected. (Not shown for Figure clarity: *p < 0.05
for 15 mM 15d-PGJ2/15d-PGJ2 vs. 15d-PGJ2/vehicle at 10 and 20 min time points; **p < 0.01 for 15d-PGJ2/AITC vs. vehicle/AITC at 10 min time
point (B) Nocifensive responses to the injection of either 15 mM AITC or 15d-PGJ2 were not reduced by 15 mM AITC pre-injection relative to
vehicle controls. (n = 8 animals per group; Values expressed as mean ± SEM). Data were analyzed using RMANOVA with Bonferonni post-hoc
comparisons.

Figure 4 Homologous and heterologous inhibition evoked by 100 μM 15d-PGJ2 vs. 100 μM AITC. A pre-pulse of 100 μM 15d-PGJ2
desensitized subsequent responses to 100 μM AITC (A) and (B). Similarly, 100 μM AITC desensitized subsequent responses to 100 μM 15d-PGJ2
and 100 μM AITC. Interstimulus intervals of 4–8 minutes were tested (8 min shown in A-D). Traces show mean ± SEM of 10–30 neurons.
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interval, two 50 μM 15d-PGJ2 pulses revealed a significant homologous desensitization of the second 15d-PGJ2
response (Figure 5A). Intriguingly, the reverse was not
evident—50 μM AITC did not inhibit the percentage of
neurons responding (39.7% vs. 38.2%) or reduce the
overall magnitude of responses to a subsequent stimulus
of 50 μM ATIC (Figure 5B). Instead, the second response to 50 μM AITC was significantly sensitized relative to the first (Figure 5C). These experiments reveal
complex concentration- and stimulus-dependent variables that affect TRPA1 activation.
15d-PGJ2 inhibits AITC, but not CAP responses

Figure 5 Homologous desensitization of 15d-PGJ2 vs. AITC is
dependent on agonist concentration. Homologous sensitization
and desensitization are agonist- and concentration-dependent. In
contrast to 50 μM 15d-PGJ2 (A), responses to 50 μM AITC sensitize
(B) significantly (C). Traces show mean ± SEM of ~30-60 DRG
neurons. Values in C represent the peak response of neurons under
each condition. **p < 0.01, ***p < 0.001. Data were analyzed using a
paired, two-tailed Student’s t-test.

shown). In experiments utilizing two 50 μM pulses of
15d-PGJ2 or two 50 μM pulses of AITC, homologous
desensitization of 15d-PGJ2, but not AITC, was maintained (Figure 5). With up to an 8 min inter-stimulus

Previous behavioral studies in rats demonstrated heterologous desensitization between TRPA1 and TRPV1
in vivo [26,28]. A pre-injection of 10 mM (0.1%) AITC
administered 15 min prior to 10 μg CAP, significantly
reduces CAP-induced nocifensive behavior compared to
vehicle pre-treatment [26]. To investigate whether 15dPGJ2 could desensitize CAP responses in vivo, we utilized the same injection protocol as with our 15d-PGJ2
and AITC desensitization studies, injecting 15 mM 15dPGJ2 1 h prior to 1.5 μg CAP. We did not observe 15dPGJ2-induced behavioral heterologous desensitization of
CAP in vivo (Figure 6A).
Next, we investigated whether 15d-PGJ2 can directly
inhibit CAP-responsiveness of DRG neurons. TRPA1 is
expressed in a subset of TRPV1-expressing neurons [1].
Several studies have documented the phenomenon of
heterologous desensitization between TRPA1 and
TRPV1 using heterologous expression systems and cultured sensory neurons [26,28-30]. To determine whether
15d-PGJ2 can inhibit subsequent responses to CAP, we
pre-exposed DRG neurons to 100 μM 15d-PGJ2 vs. vehicle and compared the number and magnitude of CAP
responders in the two groups. As illustrated in
Figure 6B, 15d-PGJ2 did not inhibit CAP responses relative to 0.1% DMSO (vehicle). Neither the total number
of neurons responding to CAP (66% vs. 58% of total
neurons, p > 0.5) nor the magnitude of these responses
(ΔF/F = 4.2 vs. 3.8, p > 0.5) was affected by preapplication of 15d-PGJ2 relative to vehicle. These findings correlate with our behavioral results and indicate
that 15d-PGJ2 does not produce heterologous inhibition
of TRPV1 via its activation of TRPA1.
Effects of 15d-PGJ2 are TRPA1-dependent

Previous studies have applied pharmacological inhibition
and gene knockout approaches to characterize the role
of TRPA1 in mechanohypersensitivity in vivo. Studies
using TRPA1−/− mice suggest that TRPA1 is not
involved in the induction of nerve injury- or
inflammation-induced hypersensitivity, as TRPA1−/−
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Figure 6 15d-PGJ2 does not affect cellular or behavioral responses to CAP. (A) 100 μM 15d-PGJ2 did not affect the response magnitude
induced by 1 μM CAP (B). In agreement with calcium imaging of DRG data, pre-treatment with 15 mM 15d-PGJ2 (10 μL ipl.) did not inhibit
behavioral responses to an 1.6 μg CAP (10 μL ipl.).

mice develop hypersensitivity equivalent to WT. However, TRPA1 antagonists (AP-18 and HC-030031) ameliorate post-insult mechanical thresholds in WT but not
TRPA1 −/− mice [21,22].
To address the possibility that 15d-PGJ2 inhibits DRG
neuron responses to AITC via a mechanism separate from
TRPA1 activation, we performed co-application studies in
DRG using HC-030031, a selective TRPA1 antagonist.
After a 4 min exposure to 100 μM 15d-PGJ2 in the presence of antagonist, 50 μM AITC responses of DRG neurons were equivalent to those after vehicle exposure
(Figure 7A and data not shown). These data support that
the inhibitory effect of 15d-PGJ2 pre-application on DRG
neuron responses to AITC is mediated via TRPA1. We
also examined the reversibility of desensitization of
TRPA1 in DRG neurons by 15d-PGJ2. As shown in
Figure 7B, 100 μM 15d-PGJ2 inhibited subsequent
responses to 50 μM AITC for up to 16 min (4–16 min
intervals tested) with continuous washout, while 50 mM
KCl responses were unaltered, indicating that general
neuronal viability remained intact.
Next we determined whether the observed reduction
in CFA-induced mechanical hypersensitivity was due to
a TRPA1-specific effect of 15d-PGJ2 by repeating the
CFA model in groups of TRPA1−/− and WT mice.
Whereas 15d-PGJ2 caused a rebound of mechanical sensitivities toward baseline in WT mice, this effect was
completely absent in TRPA1−/− mice (Figure 7C). These
data suggest that the reduction of inflammatory hypersensitivity by 15d-PGJ2 is dependent on TRPA1 and
taken together our data demonstrate a mechanism involving channel desensitization.
15d-PGJ2 tolerance and neurotoxicity

In order to evaluate the therapeutic utility of 15d-PGJ2 in
long-term inflammatory hypersensitivity, we utilized a
multi-dose protocol. We tested whether repeated doses of
15d-PGJ2, administered over the course of days, would

continue to be effective in reducing CFA-induced inflammatory mechanical hypersensitivity. As shown in Figure 8,
single daily doses of 15 mM 15d-PGJ2 (10 μL, ipl.) repeatedly attenuated mechanical hypersensitivity. To rule out
that this effect was due to toxicity or damage of TRPA1expressing peripheral fibers, we compared AITC responses
48 h after the last dose of 15d-PGJ2. We detected no difference in nocifensive behaviors of vehicle- vs. 15d-PGJ2injected groups in response to an injection of 50 mM
AITC (10 μL, ipl.) (Figure 8 inset; also note potentiation of
AITC response in CFA model).

Discussion
The primary hypothesis driving our investigation
described here is that pre-treatment with 15d-PGJ2
protects against TRPA1-mediated nociception and
hypersensitivity via inhibition of TRPA1 signaling in
nociceptive neurons. Our behavioral data correspond to
our observations in DRG sensory neurons. Our results
obtained using the acute AITC model suggest that 15dPGJ2 is sufficient to inhibit acute TRPA1-dependent
nociception. Moreover, our findings support that a
TRPA1-dependent mechanism contributes to the ability
of 15d-PGJ2 to reduce established inflammatory mechanical hypersensitivity. Finally, we have probed the utility
of 15d-PGJ2 (a TRPA1 agonist) as a potential therapeutic
and find that analgesic effects are maintained over the
course of days with repeated dosing.
Physiological relevance

All TRPA1 agonists identified to date induce nociceptive
behavior in rodents or burning sensations in humans
(for review) [31-33]. Similarly, we and others have shown
that 15d-PGJ2 (10–47.4 μg/paw) causes robust nocifensive behavior in WT, but not TRPA1−/−, mice [6,7].
These data suggest that 15d-PGJ2 (at these concentrations) induces nocifensive behavior that is specific to
TRPA1 activation. In contrast, several studies have
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Figure 7 TRPA1-dependent 15d-PGJ2-mediated inhibition of
AITC in vitro and mechanical hypersensivity in vivo. (A) In the
presence of a specific TRPA1 antagonist, HC-030031 (100 μM),
100 μM 15d-PGJ2 did not block 50 μM AITC responses. (B) We also
examined the reversibility of AITC-response inhibition in DRG
neurons by 15d-PGJ2. 100 μM 15d-PGJ2 inhibited subsequent
responses to 50 μM AITC for up to 16 min with continuous washout.
Traces depict representative cells from 1 or more experiments in
which >100 neurons were analyzed per experimental condition. (C)
15d-PGJ2 (10 μL ipl.) attenuates CFA-induced mechanical
hypersensitivity in WT but not TRPA1 −/− mice. Vehicle or 15 mM
15d-PGJ2 was injected into the hindpaw of TRPA1 or WT littermates
(n = 8 per group) 1 h prior to von Frey measurements. **p < 0.01 in
comparing WT mice injected with 15d-PGJ2 vs. WT mice injected
with vehicle. #p < 0.05, ##p < 0.01 in comparing WT mice injected
with 15d-PGJ2 vs. TRPA1 KO mice injected with 15d-PGJ2. Values
expressed as mean ± SEM. Data were analyzed using RMANOVA with
Bonferonni post-hoc comparisons.
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identified potent anti-nociceptive properties of 15dPGJ2. These studies do not report nocifensive behavior
in response to intrathecal (100 μg/site), intraganglionar
(100 ng/site), ipl. (30–300 ng/paw) or temporomandibular joint (10–100 ng/site) injection of 15d-PGJ2. Concentrations of 15d-PGJ2 shown to inhibit nociception in
these studies are typically lower than those we have
tested here (474 ng-47.4 μg/paw) [6,9,19,20].
In our view, it remains unclear whether the high concentrations of endogenous ligands we and others have
tested for their nociceptive- and anti-nociceptive effects
are physiologically relevant to pain modulation or to
TRPA1 modulation in vivo. For example, inflammatory
exudate concentrations of 15d-PGJ2 rise coincident to
the resolution of the inflammatory state. Levels detected
range between ~0.5 to 5 ng/ml—orders of magnitude
lower than those we and others have potentially introduced by ipl. injection [34,35]. There is currently no
in vitro data on the time course or kinetics of occupancy
of TRPA1 receptors by 15d-PGJ2. We are actively
attempting to investigate this question and resolve the
putative differences in agonist modulation at the channel
level. We also currently have no method of ascertaining
whether we are actively inhibiting TRPA1 channels at
sub-cutaneous nociceptive fibers at the concentration(s)
and dosing paradigm(s) we have utilized. However,
15d-PGJ2 is not broken down further enzymatically or
non-enzymatically. Though it is a reactive electrophile,
15d-PGJ2 is highly stable in aqueous phase; when aqueous
solutions are spiked with radioactively labeled 15d-PGJ2,
the compound is 100% recoverable after 48 hours [36].
This prostaglandin metabolite also has anti-inflammatory
and anti-nociceptive effects that are TRPA1-independent.
For example, Napimoga et al. (2008) reported the antinociceptive property of 15d-PGJ2 is mediated in part by
PPARγ and peripheral opioid receptors, as antagonists targeting both receptors inhibited effects of 15d-PGJ2 against
PGE2-induced “hypernociception.” This study also examined the anti-nociceptive effect of 15d-PGJ2 in the formalin model of temporomandibular joint inflammation
and ipl. delivery of carrageenan, finding that it attenuated mechanical “hypernociception” in both models.
They hypothesize that increases in the macrophage
population in the periphery contributed to the enhancement the anti-nociceptive effects of 15d-PGJ2 [19].
Whereas we are examining its action in strictly the pain
neuraxis involving primary TRPA1-expressing peripheral
nociceptors, perhaps the effects of 15d-PGJ2 on macrophages and/or opioids are downstream of signaling
through primary afferents expressing TRPA1. For instance,
activation of TRPA1-expressing nociceptors could result in
their release of factors that contribute to an immune response (i.e. 15d-PGJ2 release) or endogenous opioid
signaling.
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Figure 8 Multi-dose therapy using 15d-PGJ2 without tolerance or toxicity. Repeated ipl. injection (1 per day) of 15 mM 15d-PGJ2 attenuates
CFA- induced mechanical hypersensitivity. Note a significant rebound of mechanical thresholds toward baseline level on days 1–4 (*p < 0.05, n = 6
per group, values expressed as mean ± SEM). At Day 6 AITC responses are intact (inset). Data were analyzed using paired, two-tailed Student’s t-tests.

Differential behavioral and cellular effects of TRPA1
agonists

Previously published studies characterizing single-dose
AITC-induced nocifensive responses in mice have utilized injections of 0.1-0.75% (10–75 mM, ipl.), while
most behavioral desensitization studies using repeated
AITC stimuli have utilized ≤ 20 mM. (e.g. [3,26,27]).
Therefore, we compared behavioral desensitization to
repeated AITC- and 15d-PGJ2-stimuli at two concentrations within this range. Using our dosing protocol, nocifensive responses to AITC did not desensitize. In
contrast, 15d-PGJ2 evoked a significant desensitization
to itself and AITC. Unlike previous studies using multidose protocols, we have administered agonists 1 h apart,
which might account for the differences between our
results and those of other studies, which report
desensitization [26,29,37] or sensitization [27] by AITC.
We hypothesize that the difference in the effects of
15d-PGJ2 and AITC on heterologous and homologous
inhibition might result via differential acute and pharmacological desensitization of TRPA1 in vivo produced by
the two agonists at various concentrations. Furthermore,
topically applied and injected AITC causes an inflammatory response, including plasma extravasation and tissue
edema, while there is no evidence supporting that 15dPGJ2 promotes such responses [38,39].
To our knowledge, this is the first study to closely
examine bidirectional cross-inhibition of DRG neurons
by exposure to two different TRPA1 agonists.
The mechanisms underlying the different effects of
AITC and 15d-PGJ2 remain unclear (see also below).
Since Ca2+ imaging does not directly measure

desensitization, electrophysiological and further cellular studies are warranted to directly measure
the mechanisms of desensitization, as well as
desensitization kinetics, stimulus- and concentrationdependence. Key to our conclusions regarding inhibition of TRPA1 signaling by 15d-PGJ2, we have
attempted to make our stimulus and recording approach(es) as systematic as possible in order to reveal
differential modulation of TRPA1 by 15d-PGJ2 vs.
AITC. First, our review of the available literature indicated to us that ~100 μM concentrations of 15d-PGJ2
and AITC are saturating in calcium imaging analyses
of cultured sensory neurons [7,40]. We have confirmed
these findings using our DRG culture and stimulus
protocols. Similar to previously published EC50 data
derived from heterologous expression studies of
TRPA1 channels, we found 15d-PGJ2 and AITC to be
of similar potency in their activation of TRPA1expressing DRG neurons [6-8,11,40].
In DRG neurons, we observed strong homologous desensitization of AITC responses and crossdesensitization of 15d-PGJ2 in response to a pre-pulse of
100 μM AITC. Similarly, 100 μM 15d-PGJ2 inhibited
subsequent responses to itself and to 100 μM AITC.
Our results agree with those of Taylor-Clark et al. who
reported that pre-treatment of trigeminal sensory neurons with 100 μM AITC significantly diminished subsequent responses to both 100 μM AITC and 15d-PGJ2
[8]. While the majority of our studies examined the inhibitory efficacy of 100 μM 15d-PGJ2, we also investigated cross- and homologous desensitization using
50 μM concentrations of these compounds. We found
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that 50 μM AITC no longer exhibited these properties,
whereas 15d-PGJ2 did at this lower concentration. Our
data evince different magnitudes of homologous and
heterologous inhibition evoked by these two compounds, each with steep time- and concentration-dependence, again the mechanisms of which remain
uncertain.
A number of reports have demonstrated that similar
to heat- and capsaicin-activated TRPV1, TRPA1 exhibits strong desensitization and tachyphylaxis [1],
[29,40] [41]. However, a more recent study partially
refutes these data, showing that TRPA1 also
undergoes sensitization and trafficking to the plasma
membrane in response to AITC and inflammatory
mediators in vitro and in vivo [27]. On balance, the
results of our current study and those of previous
studies reveal that sensitization/desensitization could
be dependent on many variables, including agonist
concentration, stimulus sequence, stimulus duration
and inter-stimulus interval.
TRPV1 and TRPA1 are co-expressed in DRG
neurons with TRPA1 labeling a subset of TRPV1 neurons [1]. Studies of the two channels in CHO cell
overexpression and DRG neurons show that when
co-expressed, TRPA1 undergoes heterologous and
homologous desensitization via CAP (TRPV1 agonist)
and AITC stimuli, respectively. A proposed mechanism of TRPA1 desensitization in this manner is
through TRPV1-directed internalization [26,29]. It is
intriguing that AITC is able to inhibit subsequent behavioral and neuronal responses to CAP, but 15dPGJ2 (at the concentrations we have tested) is not,
thus further highlighting the differential effects of
these two TRPA1 agonists. Similar to Taylor-Clark
et al. but in contrast to the findings of other groups,
we find that pre-treatment with a TRPA1 agonist(in our case, 15d-PGJ2) in sensory neurons does not
inhibit subsequent responses to CAP [8]. Correspondingly, we also did not observe behavioral
desensitization to CAP as a result of 15d-PGJ2 pretreatment, indicating that the inhibition is TRPA1
specific.
Although both compounds are electrophiles that activate TRPA1 via covalent modification of key cysteine (or
other) residues, it is quite plausible that AITC and 15dPGJ2 activate the channel differently, perhaps via differential modulation of required cysteines. For instance,
there is indirect evidence that the cysteine required for
15d-PGJ2 activation in human TRPA1 is different than
that required for activation by other compounds [11].
Perhaps also the two compounds induce differential
trafficking to the plasma membrane [see 29] that is
dependent on concentration. Finally, intracellular signaling cascades upon TRPA1 activation could be ligand-
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dependent, but this has never been shown. These possibilities raise an interesting avenue of research and could
be addressed in mutagenesis studies combined with
approaches such mass spectroscopy.
TRPA1 and mechanosensitivity

We hypothesize that sufficient doses of 15d-PGJ2 effectively inhibit TRPA1 by desensitizing the channel. By applying this concept in our behavioral approaches to
understanding the modulation of TRPA1 by 15d-PGJ2 in
the CFA model of inflammatory hypersensitivity, we
have essentially obtained the same results using a channel agonist as those studies which have utilized channel
antagonists [21-23,42]. While 15d-PGJ2 had no effect on
naïve mechanical thresholds nor perturbed the development of mechanical hypersensitivity, it inhibited established inflammatory mechanical hypersensitivity in WT,
but not TRPA1−/− mice. Although it appears that TRPA1
expression in peripheral mechanonociceptors is not
required for the development of mechanical hypersensitivity, it is possible that sustained mechanical hypersensitivity results in part through an autocrine or paracrine
positive feedback mechanism involving TRPA1. As
TRPA1 is activated by products of cellular stress, factors
released by mechanical damage could feed back on the
channel. However, this possible signaling pathway does
not resolve the conundrum of why TRPA1−/− mice develop and maintain mechanical hypersensitivity, but
TRPA1 antagonists can inhibit inflammatory and neuropathic hypersensitivity via “on-target” mechanisms.
Conclusions and future directions

A goal of our studies was to determine whether 15d-PGJ2,
or any strongly desensitizing TRPA1 agonist, could be useful as a pain therapeutic. For example, for a similar channel
TRPV1, capsaicin is the active ingredient in over-thecounter and prescription topical treatments and provides
effective relief of joint pain based on its ability to desensitize
TRPV1-expressing fibers. Thus, TRPA1 agonists could
serve a similar therapeutic role. Here we describe experiments in which we administered 15d-PGJ2, beginning 1 day
after the induction of inflammation. Our dosing strategy repeatedly produced a ~2 h block of mechanical hypersensitivity as shown using the von Frey test. Our studies show
the effectiveness of administering such a dose after, but not
before, the development of inflammation or neuropathic injury. This is in accordance with the nature of pain
treatment, which is given after a patient reports discomfort
from inflammation or injury. With the route and
concentration we tested in our multi-dose experiment
(15 mM, ipl.), 15d-PGJ2 initially causes nocifensive
responses, but appears to have no pro-inflammatory or
neurotoxic effects on TRPA1-expressing neurons. Future
studies will further test the efficacy of 15d-PGJ2 as a
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therapeutic by determining a dose or route of administration
(e.g. oral or topical application) that causes minimal pain,
while providing analgesic benefits.

Methods
Animals

Experiments were performed in accordance with the
policies and recommendations of the National Institutes
of Health and the International Association for the
Study of Pain. Protocols were approved by the Animal
Care and Use Committee of Washington University
School of Medicine (St. Louis, MO). Mice were housed
at ambient (22-25°C) temperature with a 12 h light–dark
cycle. Cellular and behavioral assays were performed
using 8- to 12-wk-old male C57BL/6 J and TRPA1
knockout mice. The TRPA1−/− strain was originally
obtained from Kelvin Y. Kwan and David P. Corey [3].
Heterozygous F2 crosses were set and behavioral tests
carried out on male WT and TRPA1−/− littermates of 8–
12 weeks of age.
Behavioral assays

Animals were placed in individual Plexiglas boxes
(15X11X11 cm) either on a flat surface covered with an
absorbent liner (chemical agonist tests) or on a wire
mesh platform (von Frey tests) and acclimated for 1–2 h
to the testing environment—an individually lighted,
temperature-controlled room (22-25°C) equipped with a
white noise generator. Experimenters were blind with respect to treatment and genotype. Sample sizes are indicated in Figure legends.
Compound tests

For dose–response experiments, mice were injected
on the plantar surface of the right hindpaw with 10
μL of 0.15 (.474 μg), 1.5 (4.74 μg) or 15 mM (47.4 μg)
15d-PGJ2 diluted in 5% EtOH, 0.9% NaCl (vehicle).
Nocifensive behavior (licking and deliberate lifting and
shaking of the injected hindpaw) was recorded at 5to 10-min intervals for 1 h. For multi-dose 15d-PGJ2
experiments, mice received two ipl. injections of 10
μL 1.5 or 15 mM 15d-PGJ2 1 h apart. For multi-dose
AITC experiments, mice received two ipl. injections of
10 μL of either 0.15 mM (0.0015%), 1.5 mM (0.015%)
or 15 mM, (0.15%) AITC (diluted in mineral oil) 1 h
apart. Nocifensive behavior was recorded at 5- to
10-min intervals for 1 h.
To test for 15d-PGJ2-induced inhibition of nociceptive
responses to AITC or CAP, groups of mice were first
injected on the plantar surface of the right hindpaw with
10 μL of 1.5 or 15 mM 15d-PGJ2 or vehicle. 1 h later, an
injection of 10 μL AITC or 10 μL CAP (1.5 μg) was
administered to the same paw. For these tests,
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nocifensive behaviors (licking and deliberate lifting and
shaking of the injected hindpaw) in response to the second injection were recorded at 5- to 10-min intervals
until they completely subsided—1 h for AITC and
15 min for CAP. We also tested whether ipl. injection of
10 μL 15 mM AITC was able to inhibit subsequent
responses to an injection of 15 mM 15d-PGJ2 administered to the same paw 1 h later.
To determine whether inhibition of AITC responses
by 15d-PGJ2 were locally mediated, we also performed a
set of experiments in which we injected the left hindpaw
of two groups of mice with 15 mM 15d-PGJ2 or vehicle
and the right hindpaw with 15 mM AITC 1 h later.
Nocifensive behaviors in response to the second AITC
injection in the right hindpaw were compared between
the two groups injected with 15d-PGJ2 or vehicle in the
left hindpaw.

Mechanical hypersensitivity tests

We measured mechanical sensitivities with calibrated
von Frey hairs using the up-and-down method modified
for mice [43]. We first investigated whether an ipl. injection of 10 μL 1.5 or 15 mM 15d-PGJ2 vs. vehicle had any
effect on basal mechanical sensitivity. These experiments
were performed by acquiring baseline von Frey measurements and then injecting 15d-PGJ2 or vehicle (5% EtOH,
0.9% NaCl) into the right hindpaw. Subsequent von Frey
measurements of the ipsi- and contralateral hindpaws
were taken at 1, 2, 6, 24 and 48 h post-injection.
In a separate set of experiments, we evaluated the
effects of 15d-PGJ2 on CFA-induced inflammatory
mechanical hypersensitivity. On day 0, baseline sensitivity to von Frey stimulation was measured prior to
ipl. injection of 10 μL CFA to the right hindpaw of
mice. 24 h after CFA injection (day 1), von Frey sensitivities were measured again to determine the level of
mechanical hypersensitivity in the CFA vs. vehicle
groups. At the conclusion of these von Frey measurements, CFA-injected mice were randomly assigned to
two groups and received either an ipl. injection of 10
μL 15 mM 15d-PGJ2 or vehicle to the right hindpaw.
One h after this second injection, von Frey measurements were taken again at 1, 2, 4, 6 and 24 h post-injection. To examine the effect of repeated dosing of
15d-PGJ2, we performed this procedure as above
through day 1 and then repeated it on days 2–4. Therefore, in this set of experiments, we made von Frey measurements on days 0–4 at the following time points:
baseline (day 0), 24 h post-CFA (or vehicle) injection
(day 1) and then 1, 2 and 24 h post-15d-PGJ2 (or vehicle) injection (days 1–4). To test for maintenance of
nociceptive responses to TRPA1 activation, all mice
were administered an ipl. injection of 10 μL 50 mM
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AITC at the conclusion of our repeated 15d-PGJ2 dosing experiment.
In another set of experiments on groups of WT and
TRPA1−/− mice, we repeated this procedure as in day 1
above, but only up to 2 h post-15d-PGJ2 or vehicle injection (observed time of maximal 15d-PGJ2 effect on CFAinduced mechanical hypersensitivity).
Heat hypersensitivity test

Thermal sensitivity was measured using the Hargreaves
test [44]. Mice were placed in Plexiglas chambers on a
heated (30°C) glass surface and acclimated to the apparatus and testing environment for 1 h. Radiant heat of
constant intensity was applied to the plantar surface of
the ipsilateral hindpaw using a 390 G Plantar Test Apparatus (IITC Life Sciences, Woodland Hills, CA). Withdrawal latency was calculated as the time from stimulus
initiation until paw withdrawal with a 20 s cutoff to prevent tissue damage. The test was repeated 3 times
(~15 min between tests of same paw) and the withdrawal latencies of the 3 repetitions averaged.
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utilized the TRPA1-specific antagonist HC-030031. We
compared the magnitude and frequency of AITC
responses after 15d-PGJ2 exposure vs. 15d-PGJ2 exposure in the presence of the antagonist.
Statistical analysis

Student’s t-tests or Mann Whitney U-tests were used to
analyze data where appropriate; the tests used are indicated in the Figure legends. Repeated measures analysis
of variance (RMANOVA) with Bonferroni post-hoc correction was used to test changes in nociceptive behaviors
over time in the AITC and CAP inhibition tests and in
the CFA model of inflammatory hypersensitivity. All behavioral data were analyzed using Prism 5.0. Data from
DRG studies were analyzed using OriginPro 8.1 (OriginLab Corp., Northampton, MA 01060) and Prism 5.0
(GraphPad Software Inc., San Diego, CA). In all studies,
statistical significance is set at p < 0.05 and data are presented as mean ± S.E.M.
Compounds

DRG culture and calcium imaging

Dissociated DRG cultures derived from male C57BL/6 J
mice were prepared and plated onto polyornithine- and
laminin-coated coverslips as described [45,46]. For each
experimental condition we performed imaging on at
least 2 separate cultures derived 4 animals. These cultures yielded ~ 8 coverslips each on which we performed
paired comparisons (e.g. 100 μM AITC vs. 100 μM 15dPGJ2). Agonist-induced responses of DRG neurons were
analyzed using Fura-2 (Invitrogen) ratiometric calcium
imaging 24 h after plating. Wash, vehicle and compound
solutions contained HEPES buffered saline with 2 mM
calcium. We exposed cells to 50 mM potassium at the
end of experiments as a control for viable neurons. We
defined neuronal responses as ≥ 20% increase of the
Fura-2 ratio from baseline, with the exception of some
dose-inhibition experiments (see Results). For all experiments, the compound exposure and wash-out durations
are noted in each Figure and/or corresponding legend.
The concentrations of compounds used in crossdesensitization studies were as follows: 50 μM and
100 μM 15d-PGJ2, 50 μM and 100 μM AITC and 1 μM
CAP. We compared the responses of neurons to AITC
and CAP from the 15d-PGJ2-treated groups to those of
the vehicle-treated (0.1% DMSO) groups. To investigate
the duration of desensitization of the AITC response
induced by pre-exposure to 15d-PGJ2, we exposed the
cells to either 50 μM AITC or 100 μM 15d-PGJ2 for
1 min, washed continuously with buffer solution for up
to 16 min and then re-exposed the cells to 50 μM AITC.
Finally, to test whether inhibition of AITC responses
by 15d-PGJ2 was mediated specifically by TRPA1, we

AITC, CAP and CFA were purchased from Sigma
Chemical Company. 15d-PGJ2 was purchased from Enzo
Life Sciences. HC-030031 was purchased from Santa
Cruz. For behavioral experiments, stock solutions of
15d-PGJ2 or CAP were dissolved in ethanol and diluted
in normal saline solution (0.9% NaCl) so that the final
concentration of EtOH was ≤ 5%. Solutions of AITC
were prepared by suspending directly in mineral oil. For
calcium imaging experiments, stock solutions of 15dPGJ2, AITC and CAP were dissolved in DMSO or ethanol and used at a final solvent concentration of ≤ 0.1% in
buffer solution.
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